{"entity":{"id":"nct05144698","kind":"trial","name":"RAPA-201 Therapy of Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Rapa Therapeutics LLC, now recruiting.","summary":"RAPA-201 Therapy of Solid Tumors is a phase 1/2 interventional study registered as NCT05144698 by Rapa Therapeutics LLC, with 37 participants planned, started 2021-08-01 and due to reach its primary completion in 2026-01-01. Interventions recorded: RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody). Conditions listed: Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05144698","url":"https://clinicaltrials.gov/study/NCT05144698"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05144698","phase":"1/2","setting":"Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors","sponsor":"Rapa Therapeutics LLC","enrolled":37,"outcomes":[]},"route":"/trials/nct05144698/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}